Evidence map›Paper›PMID 36040558›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Occurrence of malignant diseases in patients with multiple sclerosis: population-based MS Registry data.

Gorica Maric, Tatjana Pekmezovic, Sarlota Mesaros, Olivera Tamas, Nikola Veselinovic, Maja Budimkic Stefanovic, Aleksa Jovanovic, Jelena Drulovic

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Gorica MaricInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Tatjana PekmezovicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Sarlota MesarosClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Belgrade, Serbia.
Olivera TamasClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Belgrade, Serbia.
Nikola VeselinovicClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Belgrade, Serbia.
Maja Budimkic StefanovicClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Belgrade, Serbia.
Aleksa JovanovicInstitute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Jelena DrulovicClinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Belgrade, Serbia. drulovicjelena@gmail.com.ORCID http://orcid.org/0000-0002-4516-3458
University of Belgrade · RS

Funding

Wellcome Trust 200110
6 · The paper itself

Abstract

introductionAmong different comorbidities occurring in multiple sclerosis (MS), the presence of malignant diseases in these patients is of the particular importance. The aim of this study was to determine the malignant diseases burden in a whole cohort of patients with MS in the Belgrade region, based on the Belgrade population registry data. MATERIAL AND

methodsThis study comprises 2725 MS patients from the MS Registry, which represents a source for all necessary demographic and clinical data. Firstly, the Registry was searched for all persons with MS who had cancer comorbidity, during the period 1996-2019. Diagnosis of cancer was validated by the patients' medical documentation. In order to investigate factors associated with the occurrence of any type of the cancer and/ or breast cancer only, in persons with MS, different logistic regression analyses were performed.

resultsA total of 64 persons with 69 malignant diseases were observed (prevalence 2.53%). The most frequent malignancies in males were skin cancer (50.0%) and in females, breast cancer (23.2%). The cumulative incidence of cancer comorbidity in persons with MS was 324.9 new cases per 100,000 person-years for the total population (137.6/100,000 in males and 403.6 per 100,000 in females). Comparison of cancer incidence rate between MS and general Belgrade population revealed lower risk for malignancy occurrence in the MS population in total (standardized incidence ratio, SIR = 0.58, 95% CI 0.16-1.49).

conclusionsOur findings demonstrate that MS patients in the Belgrade region have lower risk for the development of malignancy than age- and sex-matched general population.

Indexed as

Breast NeoplasmsMultiple SclerosisCohort StudiesFemaleHumansIncidenceMaleRegistriesSyndromeCancerMultiple sclerosisRisk factorsSIR

Identifiers

PMID36040558
OpenAlexW4293660734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.